Background/Aims: Although proinflammatory cytokine-induced disruption of intestinal epithelial barrier integrity is associated with intestinal inflammatory disease, effective treatment for barrier dysfunction is lacking. Previously, we demonstrated that rebeccamycin alleviates epithelial barrier dysfunction induced by inflammatory cytokines in Caco-2 cell monolayers; however, the underlying mechanism remained unclear. Here, we investigated the mechanism by which rebeccamycin protects the epithelial barrier function of Caco-2 cells exposed to TNF-α. Methods: To confirm the epithelial barrier function of Caco-2 cell monolayers, transepithelial electrical resistance (TER) and paracellular permeability were measured. Production levels and localization of tight junction (TJ) proteins were analyzed by immunoblot and immunofluorescence, respectively. Phosphorylated myosin light chain (pMLC) and MLC kinase (MLCK) mRNA expression levels were determined by immunoblot and quantitative RT-PCR, respectively. Results: Rebeccamycin attenuated the TNF-α-induced reduction in TER and increase in paracellular permeability. Rebeccamycin increased claudin-5 expression, but not claudin-1, -2, -4, occludin or ZO-1 expression, and prevented the TNF-α-induced changes in ZO-1 and occludin localization. Rebeccamycin suppressed the TNF-α-induced increase in MLCK mRNA expression, thus suppressing MLC phosphorylation. The rebeccamycin-mediated reduction in MLCK production and protection of epithelial barrier function were alleviated by Chk1 inhibition. Conclusion: Rebeccamycin attenuates TNF-α-induced disruption of intestinal epithelial barrier integrity by inducing claudin-5 expression and suppressing MLCK production via Chk1 activation.
Introduction
The intestinal epithelium is composed of a single-cell layer and forms a selectively permeable barrier that allows the entry of dietary nutrients, electrolytes, and water, while preventing foreign antigens, toxins, and microorganisms from penetrating the intestinal lumen and accessing the systemic circulation [1] [2] [3] [4] [5] [6] . Disruption of the barrier functions of the intestinal epithelium increases the epithelium's permeability to noxious intestinal contents and contributes to the development of intestinal inflammation; barrier defects have been associated with several intestinal diseases, including inflammatory bowel disease (IBD), celiac disease, and irritable bowel syndrome (IBS) [3, 7] .
The barrier function of the intestinal epithelium is maintained partly by tight junctions (TJs) present in the spaces between adjacent epithelial cells. TJs are the apicalmost junctional complexes and appear as a complex network of intramembranous particle strands (TJ strands) on freeze-fracture electron microscopy [8] . TJs are composed of membrane proteins such as occludin, the claudins, and junctional adhesion molecule (JAM), as well as cytoplasmic scaffolding proteins such as zonula occludens-1, -2, -3 (ZO-1, -2, -3), and cingulin [9, 10] . The intestinal barrier function in IBD patients is compromised by decreases or increases in the production levels of several TJ proteins or by changes in their distribution. In patients with Crohn's disease (CD) or ulcerative colitis (UC), the number of TJ strands is decreased and strand breaks appear; in addition, the levels of production of TJ proteins (claudin-3, -2, -5, -8, and occludin) are changed in the intestinal tissues [11] . These alterations result in impairment of the intestinal barrier, leading to increased intestinal permeability and infiltration of pathogens.
Several proinflammatory cytokines, including tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-1b, IL-6, and IL-13, are associated with the pathology of IBD [12] [13] [14] [15] . TNF-α is a crucial factor in the intestinal inflammation of CD and other inflammatory disorders [16] . Numerous clinical studies have found that TNF-α levels are significantly increased in the intestinal tissues of CD patients [17] [18] [19] , and anti-TNF-α antibody therapy is used widely to treat CD and UC patients [16, 19, 20] . Likewise, anti-TNF-α antibody is effective in animal models of intestinal inflammation [21] . TNF-α contributes to an increase in intestinal epithelial TJ permeability [22, 23] and directly activates immunoregulatory pathways. Moreover, anti-TNF-α therapy in CD patients substantially restores intestinal barrier function, indicating that dysfunction of the intestinal barrier in IBD patients is caused at least partly by the action of TNF-α. Although the mechanism underlying the effect of TNF-α on TJ permeability has not been clearly defined, several reports have revealed that myosin light chain (MLC) kinase (MLCK), an essential regulator of actomyosin function that shows increased production in the intestinal tissue of IBD patients, is a critical factor in TNF-α-induced intestinal barrier disruption [24] . TNF-α treatment induces MLCK production in intestinal epithelial cells, which leads to an increase in MLC phosphorylation and subsequent disruption of the TJ barrier [25] . Similarly, administration of an MLCK inhibitor suppresses TNF-α-induced intestinal permeability [26] , although this effect on barrier function appears to be cell-line dependent [27] . These findings suggest that MLCK is essential for the increase in intestinal permeability induced by TNF-α.
In a previous study, we showed that rebeccamycin, a DNA-damaging agent that acts by inhibiting topoisomerase I [28] , enhanced TJ barrier function in intestinal cells. Furthermore, rebeccamycin ameliorated the epithelial barrier dysfunction triggered by TNF-α and IFN-γ [29] . However, the detailed mechanism underlying the protective effect of rebeccamycin on proinflammatory cytokine-induced intestinal barrier dysfunction remains unclear. Therefore, here, we investigated the mechanistic basis for the protective effect of rebeccamycin on TNF-α-induced barrier dysfunction in Caco-2 cell monolayers.
Materials and Methods

Cell culture
The human colorectal adenocarcinoma cell line Caco-2 (HTB-37) was obtained from the American Type Culture Collection (Rockville, MD, USA). Caco-2 cells were cultured in Eagle's minimum essential medium (Nissui, Japan) supplemented with 10% FBS under 5% CO 2 at 37 °C. The number of passages used for the experiments was between 15 and 25.
Reagents and antibodies
Rebeccamycin was purchased from Sigma-Aldrich (St. Louis, MO, USA). SB-218078, a selective inhibitor of checkpoint kinase (Chk1), was purchased from Calbiochem (San Diego, CA, USA). Recombinant human TNF-α (7.6 × 10 4 IU/µg) was purchased from R&D Systems (Minneapolis, MN, USA). Rabbit anticlaudin-1 polyclonal antibody (pAb), mouse anti-claudin-4 monoclonal Ab (mAb), mouse anti-occludin mAb, and rabbit anti-ZO-1 pAb were purchased from Invitrogen (Carlsbad, CA, USA). Rabbit anti-myosin light chain 2 pAb and mouse anti-phospho-myosin light chain 2 mAb were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse anti-β-actin mAb was purchased from Sigma-Aldrich. Goat antirabbit IgG peroxidase-conjugated antibody and goat anti-mouse IgG peroxidase-conjugated antibody were purchased from Millipore (Bedford, MA, USA). Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 594 phalloidin were purchased from Molecular Probes (Eugene, OR, USA).
Measurement of intestinal barrier function
Epithelial barrier function was assessed by measuring transepithelial electrical resistance (TER) and the flux of 4-kDa fluorescein isothiocyanate (FITC)-labeled dextran in human intestinal Caco-2 cell monolayers. In the TER assay, Caco-2 cells were seeded into Transwell chambers (diameter, 6.5 mm; pore size, 0.4 µm; Corning, MA, USA) at a density of 6 × 10 4 cells/well and cultured for 10 to 14 days. After the TER values had plateaued (500 to 700 Ω•cm 2 ), TNF-α was added to the basolateral side in the absence or presence of rebeccamycin, which was applied to the apical and basolateral sides, and TER was measured with a Millicell-ERS epithelial volt-ohmmeter (Millipore Corporation, Billerica, MA, USA).
In the paracellular tracer flux assay, Caco-2 cells were cultured in Transwell chambers (diameter, 6.5 mm; pore size, 0.4 µm; Corning, MA, USA) for 10 to 14 days at a density of 6 × 10 4 cells/well. After equilibration of the culture with P buffer (10 mM HEPES [pH 7.4], 1 mM sodium pyruvate, 10 mM glucose, 3 mM CaCl 2 , and 145 mM NaCl), 100 µM dialyzed 4-kDa FITC-labeled dextran (Sigma-Aldrich, St. Louis, MO, USA) in P buffer was added to the upper chamber. After incubation of the sample for 1 h, the concentration of 4-kDa FITC-dextran in the lower chamber was determined by measuring the fluorescence with a TriStar LB 941 microplate reader (Berthold Technologies, Wildbad, Germany).
Quantitative reverse transcription -PCR (qRT-PCR) analysis
MLCK mRNA levels were analyzed by means of qRT-PCR analysis. After treatment with reagents, Caco-2 cells were washed with PBS and total RNA was extracted with Sepasol-RNA I Super G (Nakalai Tesque, Kyoto, Japan). Total RNA (3 μg) was reverse transcribed to cDNA with a cDNA synthesis kit (Roche, Mannheim, Germany) in accordance with the manufacturer's instructions. The resulting cDNA was used for qRT-PCR analysis. qRT-PCR was performed with SYBR Premix Ex Taq II (Takara, Shiga, Japan) and an Applied Biosystems StepOne Plus system (Applied Biosystems, Foster City, CA). Relative quantification was performed against a standard curve, and the values were normalized to those for the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). PCR primers were as follows: MLCK, (forward) 5′-GAGGTGCTTCAGAATGAGGACG-3′ and (reverse) 5′-GCATCAGTGACACCTGGCAACT-3′; GAPDH, (forward) 5′-GGTGGTCTCCTCTGACTTCAACA-3′ and (reverse) 5′-GTGGTCGTTGAGGGCAATG-3′.
Preparation of cell lysates and immunoblot analysis
Caco-2 cells were seeded into Transwell chambers (diameter, 24 mm; pore size, 0.4 µm; Corning) at a density of 7.5 × 10 5 cells/well and cultured for 10 to 14 days. Cells were lyzed with cell lysis buffer (10 mM Tris-HCl [pH 7.4], 0.3% SDS) containing protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail (Nakalai). Cell lysates were centrifuged at 15,600×g for 20 min at 4 °C. The supernatant of the cell lysates was run on an SDS-polyacrylamide gel and electroblotted onto a polyvinylidene difluoride (PVDF) membrane. The membranes were incubated successively with antibodies against claudin-1 and -4, occludin, ZO-1, MLC2, phospho-MLC2, or β-actin, and then with a horseradish peroxidase-conjugated anti- 
Immunofluorescence analysis
Caco-2 cells were seeded in Transwell chambers (diameter, 12 mm; pore size, 0.4 µm; Corning) at a density of 1.5 × 10 5 cells/well and cultured for 10 to 14 days. After treatment with TNF-α (10 ng/mL) or rebeccamycin (1 µM) or both, Caco-2 cells were fixed with 4% paraformaldehyde for 15 min and then permeabilized with 0.2% Triton X-100 in PBS for 5 min. Cells were then blocked for 1 h with 1% BSA in TBS buffer (20 mM Tris-HCl [pH 7.4], 40 mM NaCl) containing 0.05% Tween-20 (T-TBS) and incubated with anti-occludin or ZO-1 antibody in 1% BSA in T-TBS overnight; this was followed by an incubation with secondary fluorescence antibodies for 1 h. For F-actin staining, cells were incubated with 0.33 μM Alexa Fluor 594 phalloidin for 1 h. Immunofluorescence images were captured under a fluorescence microscope (Keyence, Tokyo, Japan).
Statistical analysis
Data are presented as means ± SD. Dunnett's or Tukey's test was used for statistical analyses. A P value of less than 0.05 was considered indicative of statistical significance.
Results
Rebeccamycin attenuates epithelial barrier dysfunction induced by TNF-α
To investigate the effect of rebeccamycin on TNF-α-mediated disruption of intestinal epithelial barrier function, we treated Caco-2 cell monolayers with 10 ng/mL TNF-α and 1 µM rebeccamycin and then measured transepithelial electrical resistance (TER) as an index of epithelial barrier function. TNF-α-induced reduction in the TER level was significantly suppressed by co-administration of rebeccamycin (Fig. 1A) . Furthermore, treatment with rebeccamycin restored the TNF-α-induced reduction in the TER level earlier than did treatment with vehicle (Fig. 1B) . We next examined the effect of rebeccamycin on the paracellular tracer permeability of Caco-2 cell monolayers treated with TNF-α. Consistent with the results of the TER analysis, TNF-α increased the paracellular flux of 4-kDa FITCdextran, as a paracellular tracer, in Caco-2 cell monolayers (Fig. 1C) , and this increased paracellular flux was significantly suppressed by co-treatment with rebeccamycin. The cytotoxicity of TNF-α was assessed by using an LDH release assay (Fig. 1D ) and detecting cleaved PARP (Fig. 1E) . TNF-α was not cytotoxic to Caco-2 cells. These results indicated that rebeccamycin ameliorated the TNF-α-induced disruption of the epithelial barrier function of Caco-2 cell monolayers.
Rebeccamycin inhibits the TNF-α-induced change in localization of tight junction components
Epithelial tight junction (TJ) barrier function is regulated by various TJ components. To investigate the effect of rebeccamycin on TJ components treated with TNF-α, or left untreated, we performed a Western blotting analysis. Total production levels of the TJ proteins claudin-1, -2, -4, and -5, occludin, and ZO-1 were not altered by TNF-α treatment ( Fig. 2A  and B ). Previous studies have also shown that TNF-α treatment has no effect on TJ proteins in Caco-2 cells [30, 31] . In cells treated with both TNF-α and rebeccamycin, rebeccamycin increased claudin-5 expression, but it had no obvious effect on the production of claudin-1, -2, or -4, occludin, or ZO-1 ( Fig. 2A and B) , suggesting that rebeccamycin-induced induction of claudin-5 expression attenuates the dysfunction of TJ barrier integrity provoked by TNF-α.
The localization of TJ components is also critically important to barrier function. Previous studies have shown that TNF-α disrupts the localization of TJ components and leads to a decrease in barrier function in Caco-2 cells [30, 31] . We also confirmed that TNF-α treatment induced a change in the distribution of ZO-1 and occludin in Caco-2 cells. Vehicle-treated Caco-2 monolayers showed ZO-1 distribution at the membrane and occludin distribution Watari et 
in a characteristic chicken-wire staining pattern. In contrast, treatment with TNF-α disrupted the normal ZO-1 and occludin patterns, and some part hardly continuous ( Fig. 3A and B) . However, co-treatment with rebeccamycin and TNF-α prevented the TNF-α-induced alteration in the distributions of ZO-1 and occludin ( Fig. 3A and B) , suggesting that rebeccamycin prevents TNF-α-induced alteration of the localization patterns of TJ proteins.
Rebeccamycin inhibits the TNF-α-mediated increase in MLC phosphorylation via a reduction in MLCK production
It is well recognized that the MLCK-mediated phosphorylation of MLC elicited by proinflammatory cytokines plays a pivotal role in the physiological and pathophysiolo- [24] . Given the protective effect of rebeccamycin on intestinal epithelial barrier function, we examined the effect of rebeccamycin on MLC phosphorylation in Caco-2 cells treated with TNF-α. Treatment of Caco-2 cells with TNF-α induced a significant increase in MLC phosphorylation without markedly changing the total MLC production level ( Fig.  4A and B) . In contrast, rebeccamycin treatment significantly attenuated the increase in MLC phosphorylation elicited by TNF-α in Caco-2 cells. MLC phosphorylation influences F-actin organization, and TNF-α treatment has been shown to change the F-actin arrangement in Caco-2 cells [32] . We, too, observed that TNF-α disrupted the assembly of F-actin, which normally stains intercellular sites along the edge of the cell (Fig. 4C and  D) . Similar to MLC phosphorylation, the TNF-α-induced disassembly of F-actin was attenuated by rebeccamycin treatment.
To examine the effect of rebeccamycin on MLCK, we evaluated MLCK production after TNF-α treatment. Rebeccamycin significantly decreased MLCK mRNA expression in a dosedependent manner (Fig. 5A) . Furthermore, rebeccamycin significantly suppressed TNF-α-induced MLCK mRNA expression (Fig. 5B) . Taken together, these findings suggested that rebeccamycin suppressed MLC phosphorylation by inhibiting MLCK production.
Rebeccamycin-induced restoration of TNF-α-mediated disruption of the barrier function depends on Chk1 activation
Our previous report showed that rebeccamycin-induced Chk1 activation Fig. 2 . Effects of TNF-α and rebeccamycin on production of tight junction proteins. Caco-2 cell monolayers were treated for 24 h with vehicle or TNF-α (10 ng/mL) in the absence or presence of rebeccamycin (1 µM). The cell lysates were collected and immunoblotted for claudin (CLDN)-1, -2, -4, -5 , occludin (OCLN), and ZO-1 (A). β-actin served as the loading control. Relative protein density was calculated as the ratio of the protein density to the density of the vehicle (B). Data are presented as means ± SD (n = 3). is essential for enhancement of barrier function in the Caco-2 cell monolayer [29] . Therefore, we investigated whether Chk1 activation was involved in the rebeccamycinmediated suppression of MLCK production. Rebeccamycin-induced reduction of MLCK mRNA expression was attenuated by the Chk1 inhibitor SB-218078 (Fig. 6A) . Next, we examined the effect of SB-218078 on the rebeccamycin-induced restoration of barrier function. Restoration of the barrier function by rebeccamycin was significantly impaired by the Chk1 inhibitor (Fig. 6B) . In contrast, the Chk1 inhibitor did not affect the TNF-α-induced reduction in barrier function. These results suggest that rebeccamycininduced restoration of the barrier function is dependent on Chk1 activity.
Discussion
We showed here that rebeccamycin ameliorates TNF-α-induced dysfunction of intestinal epithelial barrier function in Caco-2 cell monolayers. Specifically, rebeccamycin attenuates TNF-α-induced TER reduction and the increase in paracellular permeability of FD-4. In our recent study, we demonstrated that rebeccamycin enhanced TJ barrier function via upregulation of claudin-5, which strengthens the TJ barrier function of epithelial and endothelial cells, in Caco-2 cell monolayers [29] . These observations indicate that rebeccamycin has the potential to protect the epithelial barrier function against proinflammatory cytokine-mediated barrier dysfunction.
TNF-α-induced barrier dysfunction of intestinal cells can be attributed to several factors, including apoptosis, and changes in the expression or localization (or both) of TJ components such as claudin-1, claudin-2, occludin, and ZO-1 [27, 30, 31, [33] [34] [35] . In this study, immunofluorescence analysis of TJ proteins showed that TNF-α altered the localization of occludin and ZO-1 in Caco-2 cells monolayers, whereas the levels of TJ protein components such as claudin-1, -2, and -4, occludin, and ZO-1 did not change. Rebeccamycin suppressed the TNF-α-induced change in the localization of TJ components, suggesting that rebeccamycin prevented TNF-α-mediated TJ barrier dysfunction by normalizing the distribution of the affected TJ components. The TNF-α-induced alteration of the localization of the TJ components is associated with MLC phosphorylation, which can induce F-actin rearrangement [32, 36] . MLC phosphorylation is thought to be associated with the disruption of TJ assembly and impairment of intestinal epithelial barrier function [37, 38] . MLC phosphorylation is induced by various kinases, including MLCK, ROCK, and PKC [39] . Several groups have reported that increased production and activation of MLCK by TNF-α modulate MLC phosphorylation in Caco-2 cells [12, 32] . We showed here that rebeccamycin inhibited the increase in MLC phosphorylation in Caco-2 cells treated with TNF-α by reducing MLCK mRNA expression. Thus, inhibition of MLCK production may be one mechanism by which rebeccamycin attenuates the intestinal barrier dysfunction induced by TNF-α. In addition, rebeccamycin increases claudin-5 production, thus increasing the epithelial barrier integrity of Caco-2 cells [29] , indicating that rebeccamycin can ameliorate the barrier dysfunction induced by TNF-α by modulating the production of MLCK and claudin-5 (Fig. 7) .
Chk1 is a serine/threonine protein kinase that maintains genome integrity by regulating cell cycle checkpoints in response to DNA damage or incomplete DNA replication. Chk1 is regulated by ataxia-telangiectasia and RAD3-related protein under DNA damage, facilitating cell-cycle arrest and DNA repair [40, 41] . Previously, we showed that Chk1 also plays a pivotal role in the enhancement of TJ barrier function that is induced by DNA damage in Caco-2 cells [29] . We showed here that rebeccamycin inhibits MLCK production and alleviates TNF-α-induced barrier dysfunction via a mechanism that is partly dependent on the Chk1 pathway. These observations suggest that rebeccamycin-mediated Chk1 activation is essential for the protective action of rebeccamycin against TNF-α-induced intestinal epithelial barrier dysfunction. Daunorubicin and cisplatin, which both induce DNA damage and activate Chk1, suppress NF-kB-dependent transcription [42] . TNF-α-induced dysfunction of intestinal TJ barrier function involves NF-kB activation [22, 32] . The promoter region of the MLCK gene has NF-kB-binding sites, and this region is essential for the regulation of MLCK production [43, 44] . Furthermore, NF-kB activation by proinflammatory cytokines increases MLCK production by Caco-2 cells [22, 25] . These findings suggest that rebeccamycin-mediated inhibition of MLCK production is involved in NF-kB modulation. However, the mechanism of regulation of MLCK production by Chk1 activity requires further investigation.
A number of reports have revealed that proinflammatory cytokines disrupt intestinal epithelial barrier function. Whether the dysfunction of intestinal epithelial barrier function in inflammatory bowel disease is the cause or consequence of mucosal inflammation remains unclear. However, the development of strategies that address the damage to intestinal epithelial barrier function in IBD would be of value to overall therapeutic strategies for IBD [11, [45] [46] [47] [48] . We showed here that rebeccamycin inhibits the TNF-α-induced upregulation of MLC phosphorylation mediated by MLCK via Chk1 activation; this might be the molecular mechanism of the protective action of rebeccamycin against the intestinal epithelial barrier dysfunction triggered by TNF-α. Although further studies of rebeccamycin-induced enhancement of barrier function are needed, our findings suggest that an understanding of the molecular mechanism of regulation of MLCK and claudin-5 production by Chk1 might provide new insights into strategies for treating IBD.
